# CareDx, Inc.

Summary updated: 2026-10-02T11:03:32.452479Z
Canonical: https://finbar.com/research/companies/caredx-inc

## Overview

CareDx, Inc. is a precision-medicine company focused on transplant patients and organ health. Its business combines molecular testing, laboratory products, digital-health technologies and patient-support services across the pre- and post-transplant journey. Its defining tests include AlloMap and AlloSure, as well as HeartCare, which combines AlloMap Heart and AlloSure Heart. The company describes its mission as creating “life-changing solutions that enable patients to thrive.” [1](https://app.finbar.com/go?id=P3262308)[2](https://app.finbar.com/go?id=P120291916)[3](https://www.caredx.com/company)

Headquartered in Brisbane, California, CareDx also has operations in other U.S. locations, Sweden and Australia. As of December 31, 2025, it reported 765 employees, including 761 full-time employees. Revenue was $379.8 million for 2025; its 2026 interim report recorded $249.6 million for the six months ended June 30, 2026. The company was incorporated in 1998, and its first commercial product, AlloMap Heart, launched in 2005. [1](https://app.finbar.com/go?id=P3262308)[4](https://app.finbar.com/go?id=T10931450)[5](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm)[6](https://app.finbar.com/go?id=T11494222)[7](https://app.finbar.com/go?id=T16581259)[8](https://app.finbar.com/go?id=P22593057)[9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)
[1](https://app.finbar.com/go?id=P3262308)[2](https://app.finbar.com/go?id=P120291916)[3](https://www.caredx.com/company)[4](https://app.finbar.com/go?id=T10931450)[5](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm)[6](https://app.finbar.com/go?id=T11494222)[7](https://app.finbar.com/go?id=T16581259)[8](https://app.finbar.com/go?id=P22593057)[9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)[3](https://www.caredx.com/company)[5](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm)[9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)

## Products & services

CareDx’s transplant testing portfolio includes AlloSure Kidney, Heart and Lung, blood tests that use donor-derived cell-free DNA (dd-cfDNA) to monitor injury to transplanted organs. AlloSure Kidney analyzes genetic markers across the chromosomes to identify donor DNA, while AlloMap Heart uses gene-expression profiling to help identify stable heart-transplant recipients with a low probability of moderate or severe acute cellular rejection, alongside standard clinical assessment. HeartCare combines AlloMap Heart and AlloSure Heart with a Personalized Risk Report, pairing measures of immune activation and graft injury. [10](https://app.finbar.com/go?id=P38033035)[11](https://app.finbar.com/go?id=P104596697)[12](https://app.finbar.com/go?id=P6224117)[13](https://app.finbar.com/go?id=P8104646)[14](https://app.finbar.com/go?id=P38437511)[15](https://app.finbar.com/go?id=P16525353)

Other offerings include AlloCell, a cell-therapy monitoring solution for assessing engraftment and persistence, and laboratory products for transplant typing and surveillance. These include QTYPE and Olerup SSP/SBT HLA-typing products, AlloSeq Tx for high-resolution HLA typing, AlloSeq HCT for chimerism testing, and AlloSeq cfDNA for post-transplant monitoring. CareDx also offers clinical and patient-support tools, including XynQAPI for transplant quality tracking and reporting, XynCare assistance for waitlisted patients, and pharmacy and medication-management services. [16](https://app.finbar.com/go?id=P65677555)[17](https://app.finbar.com/go?id=P118214882)[18](https://app.finbar.com/go?id=P22543272)[19](https://app.finbar.com/go?id=P16992094)[20](https://app.finbar.com/go?id=P30248886)[21](https://app.finbar.com/go?id=P77152010)[22](https://app.finbar.com/go?id=P88863711)[23](https://app.finbar.com/go?id=P104401187)

In FY2025, testing services generated $274.5 million, or approximately 72.3% of total revenue; product revenue was $48.4 million (12.7%), and patient and digital solutions generated $56.9 million (15.0%). These percentages are calculated from the company’s reported category revenues and total revenue; the filing does not allocate revenue to individual named tests. [6](https://app.finbar.com/go?id=T11494222) On April 15, 2026, CareDx announced an agreement to divest its Lab Products business; the named laboratory products above describe the portfolio reported for FY2025. [24](https://www.caredx.com/newsroom/press-releases/caredx-announces-agreement-to-divest-lab-products-business-to-eurobio-scientific-for-170-million-and-announces-first-quarter-preliminary-financial-results)
[10](https://app.finbar.com/go?id=P38033035)[11](https://app.finbar.com/go?id=P104596697)[12](https://app.finbar.com/go?id=P6224117)[13](https://app.finbar.com/go?id=P8104646)[14](https://app.finbar.com/go?id=P38437511)[15](https://app.finbar.com/go?id=P16525353)[16](https://app.finbar.com/go?id=P65677555)[17](https://app.finbar.com/go?id=P118214882)[18](https://app.finbar.com/go?id=P22543272)[19](https://app.finbar.com/go?id=P16992094)[20](https://app.finbar.com/go?id=P30248886)[21](https://app.finbar.com/go?id=P77152010)[22](https://app.finbar.com/go?id=P88863711)[23](https://app.finbar.com/go?id=P104401187)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[6](https://app.finbar.com/go?id=T11494222)[24](https://www.caredx.com/newsroom/press-releases/caredx-announces-agreement-to-divest-lab-products-business-to-eurobio-scientific-for-170-million-and-announces-first-quarter-preliminary-financial-results)

## Geographic presence

The United States is CareDx’s principal disclosed sales geography. In FY2025, the company reported $359.9 million in U.S. revenue (94.8%) and $19.9 million in Rest-of-World revenue (5.2%); its filings do not break international revenue down by country. [25](https://app.finbar.com/go?id=T5563077) For the six months ended June 30, 2026, U.S. revenue was $240.3 million (96.2%) and Rest-of-World revenue was $9.4 million (3.8%). [26](https://app.finbar.com/go?id=T16581285) CareDx describes sales to countries worldwide and operations in Sweden. [27](https://app.finbar.com/go?id=P15183007)

At December 31, 2025, CareDx listed facilities in Brisbane, California (headquarters, research and development, and clinical laboratories); West Chester, Pennsylvania (sales and distribution); Omaha, Nebraska (digital solutions); Flowood, Mississippi (transplant pharmacy); Stockholm, Sweden (research and development and product manufacturing); and Fremantle, Australia (research and development). [28](https://app.finbar.com/go?id=P86696603)[29](https://app.finbar.com/go?id=P49383855) The company reported 765 employees, including 706 in the U.S. and 59 outside the U.S.; it did not provide a country-level breakdown of employees abroad. [30](https://app.finbar.com/go?id=P43991196)

The facility list is a year-end 2025 snapshot: CareDx completed the sale of its Lab Products business in June 2026, and its Q2 2026 filing states that Stockholm and Fremantle property and equipment were included in the assets sold. [31](https://app.finbar.com/go?id=P144997353)
[25](https://app.finbar.com/go?id=T5563077)[25](https://app.finbar.com/go?id=T5563077)[26](https://app.finbar.com/go?id=T16581285)[26](https://app.finbar.com/go?id=T16581285)[27](https://app.finbar.com/go?id=P15183007)[28](https://app.finbar.com/go?id=P86696603)[29](https://app.finbar.com/go?id=P49383855)[30](https://app.finbar.com/go?id=P43991196)[31](https://app.finbar.com/go?id=P144997353)

## Business segments

CareDx, Inc. reports one operating and reportable segment, rather than multiple business segments. Its 2025 revenue disclosures separately present three categories: testing services, products, and patient and digital solutions. [32](https://app.finbar.com/go?id=P38688730)[33](https://app.finbar.com/go?id=P22210271)

For the year ended December 31, 2025, testing services— including laboratory testing—generated $274.5 million, approximately 72.3% of total revenue. Product revenue, from laboratory products, was $48.4 million (12.7%); patient and digital solutions revenue was $56.9 million (15.0%). The percentages are calculated from the reported category and total revenue amounts. [6](https://app.finbar.com/go?id=T11494222)[1](https://app.finbar.com/go?id=P3262308)
[32](https://app.finbar.com/go?id=P38688730)[33](https://app.finbar.com/go?id=P22210271)[6](https://app.finbar.com/go?id=T11494222)[1](https://app.finbar.com/go?id=P3262308)[34](https://investors.caredx.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=19183984)

## Company history

CareDx was incorporated in Delaware in December 1998 as Hippocratic Engineering, Inc. It subsequently operated as BioCardia, Expression Diagnostics and XDx before adopting the CareDx name in March 2014; the company’s filings do not identify its founders. [35](https://app.finbar.com/go?id=P16102038) Its AlloMap Heart test became its first commercial product in 2005. [9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)

In 2016, CareDx acquired Allenex, expanding into HLA typing products. [36](https://app.finbar.com/go?id=P118863468) It launched AlloSure Kidney in 2017 and introduced HeartCare, combining AlloMap and AlloSure Heart, in 2018. [37](https://investors.caredx.com/news/news-details/2018/CareDx-Reports-Fourth-Quarter-and-FY2017-Financial-Results-03-22-2018/default.aspx) [38](https://investors.caredx.com/news/news-details/2018/CareDx-Launches-HeartCare-for-Heart-Transplant-Recipients-04-10-2018/default.aspx) The company agreed to acquire OTTR Complete Transplant Management in 2019, and in 2020 Reginald Seeto became president and CEO, succeeding Peter Maag, who became executive chairman. [39](https://investors.caredx.com/news/news-details/2019/CareDx-Agrees-to-Acquire-OTTR-Complete-Transplant-Management-04-25-2019/default.aspx) [40](https://investors.caredx.com/news/news-details/2020/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020/default.aspx)

CareDx launched AlloSure Lung in 2021, acquired transplant logistics company MediGO in 2023, and appointed John W. Hanna president and CEO in 2024. [41](https://investors.caredx.com/news/news-details/2021/AlloSure-the-First-dd-cfDNA-in-Heart-and-Kidney-Transplantation-Launches-for-Lung-Transplant-Patients-10-12-2021/default.aspx) [42](https://investors.caredx.com/news/news-details/2023/CareDx-Acquires-MediGO-an-Organ-Transplant-Supply-Chain-and-Logistics-Company/default.aspx) [43](https://investors.caredx.com/news/news-details/2024/CareDx-Appoints-John-W--Hanna-as-its-New-President-and-Chief-Executive-Officer/default.aspx) In 2026, CareDx completed its acquisition of Naveris, extending its business into viral-mediated cancer minimal residual disease testing. [44](https://app.finbar.com/go?id=P144998065)
[35](https://app.finbar.com/go?id=P16102038)[9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)[36](https://app.finbar.com/go?id=P118863468)[37](https://investors.caredx.com/news/news-details/2018/CareDx-Reports-Fourth-Quarter-and-FY2017-Financial-Results-03-22-2018/default.aspx)[38](https://investors.caredx.com/news/news-details/2018/CareDx-Launches-HeartCare-for-Heart-Transplant-Recipients-04-10-2018/default.aspx)[39](https://investors.caredx.com/news/news-details/2019/CareDx-Agrees-to-Acquire-OTTR-Complete-Transplant-Management-04-25-2019/default.aspx)[40](https://investors.caredx.com/news/news-details/2020/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020/default.aspx)[41](https://investors.caredx.com/news/news-details/2021/AlloSure-the-First-dd-cfDNA-in-Heart-and-Kidney-Transplantation-Launches-for-Lung-Transplant-Patients-10-12-2021/default.aspx)[42](https://investors.caredx.com/news/news-details/2023/CareDx-Acquires-MediGO-an-Organ-Transplant-Supply-Chain-and-Logistics-Company/default.aspx)[43](https://investors.caredx.com/news/news-details/2024/CareDx-Appoints-John-W--Hanna-as-its-New-President-and-Chief-Executive-Officer/default.aspx)[44](https://app.finbar.com/go?id=P144998065)[9](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)[37](https://investors.caredx.com/news/news-details/2018/CareDx-Reports-Fourth-Quarter-and-FY2017-Financial-Results-03-22-2018/default.aspx)[38](https://investors.caredx.com/news/news-details/2018/CareDx-Launches-HeartCare-for-Heart-Transplant-Recipients-04-10-2018/default.aspx)[39](https://investors.caredx.com/news/news-details/2019/CareDx-Agrees-to-Acquire-OTTR-Complete-Transplant-Management-04-25-2019/default.aspx)[40](https://investors.caredx.com/news/news-details/2020/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020/default.aspx)[41](https://investors.caredx.com/news/news-details/2021/AlloSure-the-First-dd-cfDNA-in-Heart-and-Kidney-Transplantation-Launches-for-Lung-Transplant-Patients-10-12-2021/default.aspx)[42](https://investors.caredx.com/news/news-details/2023/CareDx-Acquires-MediGO-an-Organ-Transplant-Supply-Chain-and-Logistics-Company/default.aspx)[43](https://investors.caredx.com/news/news-details/2024/CareDx-Appoints-John-W--Hanna-as-its-New-President-and-Chief-Executive-Officer/default.aspx)

## Sources

1. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P3262308)
2. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P120291916)
3. [www.caredx.com](https://www.caredx.com/company)
4. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10931450)
5. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm)
6. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T11494222)
7. [CareDx, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16581259)
8. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22593057)
9. [investors.caredx.com](https://investors.caredx.com/news/news-details/2022/CareDx-Reports-Over-200000-Heart-Transplant-Patient-Results-Served-04-14-2022/default.aspx)
10. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P38033035)
11. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P104596697)
12. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P6224117)
13. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P8104646)
14. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P38437511)
15. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P16525353)
16. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P65677555)
17. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P118214882)
18. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22543272)
19. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P16992094)
20. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P30248886)
21. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P77152010)
22. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P88863711)
23. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P104401187)
24. [www.caredx.com](https://www.caredx.com/newsroom/press-releases/caredx-announces-agreement-to-divest-lab-products-business-to-eurobio-scientific-for-170-million-and-announces-first-quarter-preliminary-financial-results)
25. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T5563077)
26. [CareDx, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16581285)
27. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P15183007)
28. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P86696603)
29. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P49383855)
30. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P43991196)
31. [CareDx, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144997353)
32. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P38688730)
33. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P22210271)
34. [investors.caredx.com](https://investors.caredx.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=19183984)
35. [CareDx, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P16102038)
36. [CareDx, Inc. — Transcript (2016 Q 1)](https://app.finbar.com/go?id=P118863468)
37. [investors.caredx.com](https://investors.caredx.com/news/news-details/2018/CareDx-Reports-Fourth-Quarter-and-FY2017-Financial-Results-03-22-2018/default.aspx)
38. [investors.caredx.com](https://investors.caredx.com/news/news-details/2018/CareDx-Launches-HeartCare-for-Heart-Transplant-Recipients-04-10-2018/default.aspx)
39. [investors.caredx.com](https://investors.caredx.com/news/news-details/2019/CareDx-Agrees-to-Acquire-OTTR-Complete-Transplant-Management-04-25-2019/default.aspx)
40. [investors.caredx.com](https://investors.caredx.com/news/news-details/2020/Peter-Maag-Appointed-Executive-Chairman-of-the-Board-of-Directors-of-CareDx-Reginald-Seeto-Appointed-President-and-CEO-10-29-2020/default.aspx)
41. [investors.caredx.com](https://investors.caredx.com/news/news-details/2021/AlloSure-the-First-dd-cfDNA-in-Heart-and-Kidney-Transplantation-Launches-for-Lung-Transplant-Patients-10-12-2021/default.aspx)
42. [investors.caredx.com](https://investors.caredx.com/news/news-details/2023/CareDx-Acquires-MediGO-an-Organ-Transplant-Supply-Chain-and-Logistics-Company/default.aspx)
43. [investors.caredx.com](https://investors.caredx.com/news/news-details/2024/CareDx-Appoints-John-W--Hanna-as-its-New-President-and-Chief-Executive-Officer/default.aspx)
44. [CareDx, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P144998065)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.